Yamada K, Ohno R, Oguri T, Kamiya O, Yokomaku S, Kobayashi M, Nishiwaki H, Tanaka M, Inagaki J, Mitomo Y
Dept. of Internal Medicine, Branch Hospital of Nagoya University Hospital, Japan.
Gan To Kagaku Ryoho. 1991 Nov;18(14):2447-52.
Late phase II trial of MST-16 for malignant lymphoma was conducted by the multi-institutions collaboration. Out of 34 patients entered, 29 were evaluated for efficacy as well as side effects. One complete response and 8 partial responses were achieved by the treatment of MST-16. The factors which affect the response rate were prior chemotherapies, stage of disease and performance status. The main toxicities were bone marrow suppression and G-I disorders. Leukopenia was observed in 72.4% of patients, thrombocytopenia in 44.8% and nausea/vomiting in 31.0%. Patients recovered from these side effects by discontinuation of the MST-16 therapy.
MST - 16用于恶性淋巴瘤的II期晚期试验由多机构合作开展。在入组的34例患者中，29例接受了疗效和副作用评估。MST - 16治疗取得了1例完全缓解和8例部分缓解。影响缓解率的因素有既往化疗、疾病分期和体能状态。主要毒性反应为骨髓抑制和胃肠道紊乱。72.4%的患者出现白细胞减少，44.8%出现血小板减少，31.0%出现恶心/呕吐。通过停用MST - 16治疗，患者从这些副作用中恢复。
